Pharmacological MRI in animal models: A useful tool for 5-HT research?

Neuropharmacology

Volumn 55, Issue 6, 2008, Pages 1038-1047

  Martin, Chris ^a   Sibson, Nicola R ^a  

^a Radiobiology Research Institute   (United Kingdom)

Author keywords

5 HT; Magnetic resonance imaging; Pharmacological MRI; Rat

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; AMPHETAMINE; ARIPIPRAZOLE; CITALOPRAM; DEXFENFLURAMINE; GADOLINIUM; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2C RECEPTOR; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ARTICLE; BRAIN BLOOD FLOW; BRAIN MAPPING; CLINICAL TRIAL; DRUG RECEPTOR BINDING; FUNCTIONAL ANATOMY; HUMAN; NERVE CELL; NEUROIMAGING; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOLOGICAL MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIGNAL DETECTION;

ANIMALS; BRAIN; BRAIN MAPPING; HUMANS; MAGNETIC RESONANCE IMAGING; MODELS, ANIMAL; NEUROPHARMACOLOGY; RATS; SEROTONIN;

EID: 53449098831     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.08.014     Document Type: Article

References (116)

1. Ackermann R.F., Finch D.M., Babb T.L., and Engel Jr. J. Increased glucose metabolism during long-duration recurrent inhibition of hippocampal pyramidal cells. J. Neurosci. 4 (1984) 251-264
2. Ances B.M., Leontiev O., Perthen J.E., Liang C., Lansing A.E., and Buxton R.B. Regional differences in the coupling of cerebral blood flow and oxygen metabolism changes in response to activation: implications for BOLD-fMRI. NeuroImage 39 (2008) 1510-1521
3. Arce E., Simmons A.N., Lovero K.L., Stein M.B., and Paulus M.P. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology (Berl.) 196 (2008) 661-672
4. Arthurs O.J., and Boniface S. How well do we understand the neural origins of the fMRI BOLD signal?. Trends Neurosci. 25 (2002) 27-31
5. Attwell D., and Iadecola C. The neural basis of functional brain imaging signals. Trends Neurosci. 25 (2002) 621-625
6. Austin V.C., Blamire A.M., Allers K.A., Sharp T., Styles P., Matthews P.M., and Sibson N.R. Confounding effects of anesthesia on functional activation in rodent brain: a study of halothane and alpha-chloralose anesthesia. NeuroImage 24 (2005) 92-100
7. Aznavour N., Rbah L., Riad M., Reilhac A., Costes N., Descarries L., and Zimmer L. A PET imaging study of 5-HT(1A) receptors in cat brain after acute and chronic fluoxetine treatment. NeuroImage 33 (2006) 834-842
8. Berwick J., Johnston D., Jones M., Martindale J., Martin C., Kennerley A.J., Redgrave P., and Mayhew J.E. Fine detail of neurovascular coupling revealed by spatiotemporal analysis of the hemodynamic response to single whisker stimulation in rat barrel cortex. J. Neurophysiol. 99 (2008) 787-798
9. Berwick J., Martin C., Martindale J., Jones M., Johnston D., Zheng Y., Redgrave P., and Mayhew J. Hemodynamic response in the unanesthetized rat: intrinsic optical imaging and spectroscopy of the barrel cortex. J. Cereb. Blood Flow Metab. 22 (2002) 670-679
10. Blamire A.M. The technology of MRI - the next 10 years?. Br. J. Radiol. 81 (2008) 601-617
11. Bonvento G., Charbonne R., Correze J.L., Borredon J., Seylaz J., and Lacombe P. Is alpha-chloralose plus halothane induction a suitable anesthetic regimen for cerebrovascular research?. Brain Res. 665 (1994) 213-221
12. Boothman L., Raley J., Denk F., Hirani E., and Sharp T. In vivo evidence that 5-HT(2C) receptors inhibit 5-HT neuronal activity via a GABAergic mechanism. Br. J. Pharmacol. 149 (2006) 861-869
13. Borsook D., Becerra L., and Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat. Rev. Drug Discov. 5 (2006) 411-424
14. Caesar K., Thomsen K., and Lauritzen M. Dissociation of spikes, synaptic activity, and activity-dependent increments in rat cerebellar blood flow by tonic synaptic inhibition. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 16000-16005
15. Chen Y.C., Galpern W.R., Brownell A.L., Matthews R.T., Bogdanov M., Isacson O., Keltner J.R., Beal M.F., Rosen B.R., and Jenkins B.G. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med. 38 (1997) 389-398
16. Cohen Z., Bonvento G., Lacombe P., and Hamel E. Serotonin in the regulation of brain microcirculation. Prog. Neurobiol. 50 (1996) 335-362
17. Cohen Z., Bouchelet I., Olivier A., Villemure J.G., Ball R., Stanimirovic D.B., and Hamel E. Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization. J. Cereb. Blood Flow Metab. 19 (1999) 908-917
18. Cryan J.F., Valentino R.J., and Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev. 29 (2005) 547-569
19. Culver J.P., Siegel A.M., Franceschini M.A., Mandeville J.B., and Boas D.A. Evidence that cerebral blood volume can provide brain activation maps with better spatial resolution than deoxygenated hemoglobin. NeuroImage 27 (2005) 947-959
20. Del-Ben C.M., Deakin J.F., McKie S., Delvai N.A., Williams S.R., Elliott R., Dolan M., and Anderson I.M. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology 30 (2005) 1724-1734
21. Devor A., Tian P., Nishimura N., Teng I.C., Hillman E.M., Narayanan S.N., Ulbert I., Boas D.A., Kleinfeld D., and Dale A.M. Suppressed neuronal activity and concurrent arteriolar vasoconstriction may explain negative blood oxygenation level-dependent signal. J. Neurosci. 27 (2007) 4452-4459
22. Dieguez G., Gomez B., and Lluch S. Analysis of the cerebrovascular effects of 5-hydroxytryptamine in unanesthetized goats. J. Pharmacol. Exp. Ther. 216 (1981) 599-603
23. Dixon A.L., Prior M., Morris P.M., Shah Y.B., Joseph M.H., and Young A.M. Dopamine antagonist modulation of amphetamine response as detected using pharmacological MRI. Neuropharmacology 48 (2005) 236-245
24. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Holt D., Greer P.J., Huang Y., Gautier C., and Mathis C. PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry 46 (1999) 1375-1387
25. Drevets W.C. Neuroimaging studies of mood disorders. Biol. Psychiatry 48 (2000) 813-829
26. Duong T.Q., Kim D.S., Ugurbil K., and Kim S.G. Localized cerebral blood flow response at submillimeter columnar resolution. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10904-10909
27. Freo U., Merico A., Ermani M., and Ori C. Cerebral metabolic effects of fluoxetine, fluvoxamine, paroxetine and sertraline in the conscious rat. Neurosci. Lett. 436 (2008) 148-152
28. Friston K.J. Functional and effective connectivity in neuroimaging: a synthesis. Hum. Brain Mapp. 2 (1994) 56-78
29. Frostig R.D., Lieke E.E., Ts'o D.Y., and Grinvald A. Cortical functional architecture and local coupling between neuronal activity and the microcirculation revealed by in vivo high-resolution optical imaging of intrinsic signals. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 6082-6086
30. Harel N., Lee S.P., Nagaoka T., Kim D.S., and Kim S.G. Origin of negative blood oxygenation level-dependent fMRI signals. J. Cereb. Blood Flow Metab. 22 (2002) 908-917
31. Hariri A.R., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., Egan M.F., and Weinberger D.R. Serotonin transporter genetic variation and the response of the human amygdala. Science 297 (2002) 400-403
32. Harmer C.J., Mackay C.E., Reid C.B., Cowen P.J., and Goodwin G.M. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol. Psychiatry 59 (2006) 816-820
33. Hirani E., Opacka-Juffry J., Gunn R., Khan I., Sharp T., and Hume S. Pindolol occupancy of 5-HT(1A) receptors measured in vivo using small animal positron emission tomography with carbon-11 labeled WAY 100635. Synapse 36 (2000) 330-341
34. 11C]MDL 100907: small animal PET and gene expression studies. Synapse 50 (2003) 251-260
35. Honey G., and Bullmore E. Human pharmacological MRI. Trends Pharmacol. Sci. 25 (2004) 366-374
36. 11C]DASB. Eur. J. Nucl. Med. 27 (2000) 1719-1722
37. Houston G.C., Papadakis N.G., Carpenter T.A., Hall L.D., Mukherjee B., James M.F., and Huang C.L. Mapping of brain activation in response to pharmacological agents using fMRI in the rat. Magn. Reson. Imaging 19 (2001) 905-919
38. Hume S., Hirani E., Opacka-Juffry J., Myers R., Townsend C., Pike V., and Grasby P. Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(IA) receptors in rat brain, assessed using in vivo microdialysis nd PET after fenfluramine. Synapse 41 (2001) 150-159
39. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5 (2004) 347-360
40. Jenkins B.G., Sanchez-Pernaute R., Brownell A.L., Chen Y.C., and Isacson O. Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J. Neurosci. 24 (2004) 9553-9560
41. Jezzard P., and Buxton R.B. The clinical potential of functional magnetic resonance imaging. J. Magn. Reson. Imaging 23 (2006) 787-793
42. Jones S.C., Williams J.L., Shea M., Easley K.A., and Wei D. Cortical cerebral blood flow cycling: anesthesia and arterial blood pressure. Am. J. Physiol. 268 (1995) H569-H575
43. Judenhofer M.S., Wehrl H.F., Newport D.F., Catana C., Siegel S.B., Becker M., Thielscher A., Kneilling M., Lichy M.P., Eichner M., Klingel K., Reischl G., Widmaier S., Rocken M., Nutt R.E., Machulla H.J., Uludag K., Cherry S.R., Claussen C.D., and Pichler B.J. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med. 14 (2008) 459-465
44. Kaisti K.K., Langsjo J.W., Aalto S., Oikonen V., Sipila H., Teras M., Hinkka S., Metsahonkala L., and Scheinin H. Effects of sevoflurane, propofol, and adjunct nitrous oxide on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 99 (2003) 603-613
45. Kannurpatti S.S., and Biswal B.B. Negative functional response to sensory stimulation and its origins. J. Cereb. Blood Flow Metab. 24 (2004) 703-712
46. Lahti K.M., Ferris C.F., Li F., Sotak C.H., and King J.A. Imaging brain activity in conscious animals using functional MRI. J. Neurosci. Methods 82 (1998) 75-83
47. Lahti K.M., Ferris C.F., Li F., Sotak C.H., and King J.A. Comparison of evoked cortical activity in conscious and propofol-anesthetized rats using functional MRI. Magn. Reson. Med. 41 (1999) 412-416
48. Lauritzen M. On the neural basis of fMRI signals. Clin. Neurophysiol. 119 (2008) 729-730
49. Leslie R.A., and James M.F. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol. Sci. 21 (2000) 314-318
50. Lindauer U., Villringer A., and Dirnagl U. Characterization of CBF response to somatosensory stimulation: model and influence of anesthetics. Am. J. Physiol. 264 (1993) H1223-H1228
51. Linde R., Schmalbruch I.K., Paulson O.B., and Madsen P.L. The Kety-Schmidt technique for repeated measurements of global cerebral blood flow and metabolism in the conscious rat. Acta Physiol. Scand. 165 (1999) 395-401
52. Logothetis N.K. MR imaging in the non-human primate: studies of function and of dynamic connectivity. Curr. Opin. Neurobiol. 13 (2003) 630-642
53. Logothetis N.K. The ins and outs of fMRI signals. Nat. Neurosci. 10 (2007) 1230-1232
54. Logothetis N.K. What we can do and what we cannot do with fMRI. Nature 453 (2008) 869-878
55. Logothetis N.K., Pauls J., Augath M., Trinath T., and Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature 412 (2001) 150-157
56. Logothetis N.K., and Wandell B.A. Interpreting the BOLD signal. Annu. Rev. Physiol. 66 (2004) 735-769
57. Loubinoux I., Boulanouar K., Ranjeva J.P., Carel C., Berry I., Rascol O., Celsis P., and Chollet F. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. J. Cereb. Blood Flow Metab. 19 (1999) 1365-1375
58. Loubinoux I., Pariente J., Rascol O., Celsis P., and Chollet F. Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects. Neuropsychologia 40 (2002) 1815-1821
59. Luo F., Wu G., Li Z., and Li S.J. Characterization of effects of mean arterial blood pressure induced by cocaine and cocaine methiodide on BOLD signals in rat brain. Magn. Reson. Med. 49 (2003) 264-270
60. Malonek D., and Grinvald A. Interactions between electrical activity and cortical microcirculation revealed by imaging spectroscopy: implications for functional brain mapping. Science 272 (1996) 551-554
61. Mandeville J.B., Jenkins B.G., Kosofsky B.E., Moskowitz M.A., Rosen B.R., and Marota J.J. Regional sensitivity and coupling of BOLD and CBV changes during stimulation of rat brain. Magn. Reson. Med. 45 (2001) 443-447
62. Martin C., Jones M., Martindale J., and Mayhew J. Haemodynamic and neural responses to hypercapnia in the awake rat. Eur. J. Neurosci. 24 (2006) 2601-2610
63. Martin C., Martindale J., Berwick J., and Mayhew J. Investigating neural-hemodynamic coupling and the hemodynamic response function in the awake rat. NeuroImage 32 (2006) 33-48
64. Mathiesen C., Caesar K., Akgoren N., and Lauritzen M. Modification of activity-dependent increases of cerebral blood flow by excitatory synaptic activity and spikes in rat cerebellar cortex. J. Physiol. 512 Pt 2 (1998) 555-566
65. McAteer M.A., Sibson N.R., von Zur Muhlen C., Schneider J.E., Lowe A.S., Warrick N., Channon K.M., Anthony D.C., and Choudhury R.P. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat. Med. 13 (2007) 1253-1258
66. McKie S., Del-Ben C., Elliott R., Williams S., del Vai N., Anderson I., and Deakin J.F. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl.) 180 (2005) 680-686
67. Meltzer C.C., Price J.C., Mathis C.A., Greer P.J., Cantwell M.N., Houck P.R., Mulsant B.H., Ben-Eliezer D., Lopresti B., DeKosky S.T., and Reynolds III C.F. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am. J. Psychiatry 156 (1999) 1871-1878
68. Nair D.G. About being BOLD. Brain Res. Brain Res. Rev. 50 (2005) 229-243
69. Nehls D.G., Park C.K., MacCormack A.G., and McCulloch J. The effects of N-methyl-d-aspartate receptor blockade with MK-801 upon the relationship between cerebral blood flow and glucose utilisation. Brain Res. 511 (1990) 271-279
70. Nguyen T.V., Brownell A.L., Iris Chen Y.C., Livni E., Coyle J.T., Rosen B.R., Cavagna F., and Jenkins B.G. Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse 36 (2000) 57-65
71. Nir Y., Dinstein I., Malach R., and Heeger D.J. BOLD and spiking activity. Nat. Neurosci. 11 (2008) 523-524
72. Nishizawa S., Benkelfat C., Young S.N., Leyton M., Mzengeza S., de Montigny C., Blier P., and Diksic M. Differences between males and females in rates of serotonin synthesis in human brain. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 5308-5313
73. Nordquist R.E., Risterucci C., Moreau J.L., von Kienlin M., Kunnecke B., Maco M., Freichel C., Riemer C., and Spooren W. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology 54 (2008) 405-416
74. Ogawa S., Lee T.M., Kay A.R., and Tank D.W. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 9868-9872
75. Ogawa S., Lee T.M., Stepnoski R., Chen W., Zhu X.H., and Ugurbil K. An approach to probe some neural systems interaction by functional MRI at neural time scale down to milliseconds. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 11026-11031
76. Oz G., Berkich D.A., Henry P.G., Xu Y., LaNoue K., Hutson S.M., and Gruetter R. Neuroglial metabolism in the awake rat brain: CO2 fixation increases with brain activity. J. Neurosci. 24 (2004) 11273-11279
77. Peeters R.R., Tindemans I., De Schutter E., and Van der Linden A. Comparing BOLD fMRI signal changes in the awake and anesthetized rat during electrical forepaw stimulation. Magn. Reson. Imaging 19 (2001) 821-826
78. Peeters R.R., and Van der Linden A. A data post-processing protocol for dynamic MRI data to discriminate brain activity from global physiological effects. Magn. Reson. Imaging 20 (2002) 503-510
79. Preece M.A., Blamire A., Styles P., Sharp T., and Sibson N.R. Pharmacological modulation of the serotonergic system in rat brain detected by fMRI. ISMRM Proc. 14 (2006) 3274
80. Preece M.A., Sibson N.R., Raley J.M., Blamire A., Styles P., and Sharp T. Region-specific effects of a tyrosine-free amino acid mixture on amphetamine-induced changes in BOLD fMRI signal in the rat brain. Synapse 61 (2007) 925-932
81. Qiao M., Rushforth D., Wang R., Shaw R.A., Tomanek B., Dunn J.F., and Tuor U.I. Blood-oxygen-level-dependent magnetic resonance signal and cerebral oxygenation responses to brain activation are enhanced by concurrent transient hypertension in rats. J. Cereb. Blood Flow Metab. 27 (2007) 1280-1289
82. Rabiner E. Imaging technologies in drug development: anxiety and depression. Drug Discov. Today Technol. 2 (2005) 323-327
83. Raley J., Davies A.E., Sharp T., Anthony D.C., and Sibson N.R. Systemic infection alters 5-HT function in the rodent brain as demonstrated by phMRI. ISMRM Proc. 16 (2008) 2497
84. Rauch A., Rainer G., Augath M., Oeltermann A., and Logothetis N.K. Pharmacological MRI combined with electrophysiology in non-human primates: effects of Lidocaine on primary visual cortex. NeuroImage 40 (2008) 590-600
85. Rauch A., Rainer G., and Logothetis N.K. The effect of a serotonin-induced dissociation between spiking and perisynaptic activity on BOLD functional MRI. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 6759-6764
86. Riera J.J., Schousboe A., Waagepetersen H.S., Howarth C., and Hyder F. The micro-architecture of the cerebral cortex: functional neuroimaging models and metabolism. NeuroImage 40 (2008) 1436-1459
87. Rupniak N.M. Animal models of depression: challenges from a drug development perspective. Behav. Pharmacol. 14 (2003) 385-390
88. Scanley B.E., Kennan R.P., and Gore J.C. Changes in rat cerebral blood volume due to modulation of the 5-HT(1A) receptor measured with susceptibility enhanced contrast MRI. Brain Res. 913 (2001) 149-155
89. Schwarz A.J., Gozzi A., Reese T., and Bifone A. In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI. NeuroImage 34 (2007) 1627-1636
90. 3 receptor antagonist SB277011A. Magn. Reson. Imaging 25 (2007) 811-820
91. Shah Y.B., and Marsden C.A. The application of functional magnetic resonance imaging to neuropharmacology. Curr. Opin. Pharmacol. 4 (2004) 517-521
92. Sheline Y.I., Mintun M.A., Moerlein S.M., and Snyder A.Z. Greater loss of 5-HT(2A) receptors in midlife than in late life. Am. J. Psychiatry 159 (2002) 430-435
93. Sheth S.A., Nemoto M., Guiou M., Walker M., Pouratian N., Hageman N., and Toga A.W. Columnar specificity of microvascular oxygenation and volume responses: implications for functional brain mapping. J. Neurosci. 24 (2004) 634-641
94. Shmuel A., Augath M., Oeltermann A., and Logothetis N.K. Negative functional MRI response correlates with decreases in neuronal activity in monkey visual area V1. Nat. Neurosci. 9 (2006) 569-577
95. Shtoyerman E., Arieli A., Slovin H., Vanzetta I., and Grinvald A. Long-term optical imaging and spectroscopy reveal mechanisms underlying the intrinsic signal and stability of cortical maps in V1 of behaving monkeys. J. Neurosci. 20 (2000) 8111-8121
96. Sibson N.R., Blamire A.M., Bernades-Silva M., Laurent S., Boutry S., Muller R.N., Styles P., and Anthony D.C. MRI detection of early endothelial activation in brain inflammation. Magn. Reson. Med. 51 (2004) 248-252
97. Sicard K., Shen Q., Brevard M.E., Sullivan R., Ferris C.F., King J.A., and Duong T.Q. Regional cerebral blood flow and BOLD responses in conscious and anesthetized rats under basal and hypercapnic conditions: implications for functional MRI studies. J. Cereb. Blood Flow Metab. 23 (2003) 472-481
98. Silva A.C., and Koretsky A.P. Laminar specificity of functional MRI onset times during somatosensory stimulation in rat. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 15182-15187
99. Silva A.C., Zhang W., Williams D.S., and Koretsky A.P. Multi-slice MRI of rat brain perfusion during amphetamine stimulation using arterial spin labeling. Magn. Reson. Med. 33 (1995) 209-214
100. Smirnakis S.M., Schmid M.C., Weber B., Tolias A.S., Augath M., and Logothetis N.K. Spatial specificity of BOLD versus cerebral blood volume fMRI for mapping cortical organization. J. Cereb. Blood Flow Metab. 27 (2007) 1248-1261
101. Sloan H., Austin V.C., Lowe A.S., O'Neill M., Matthews P.M., and Sibson N.R. Do differences in BOLD and CBV responses to cortical stimulation during mGluR5 blockade refect regional differences in neurovascular coupling mechanisms?. ISMRM Proc. 15 (2007) 2018
102. Smith A.T., Williams A.L., and Singh K.D. Negative BOLD in the visual cortex: evidence against blood stealing. Hum. Brain Mapp. 21 (2004) 213-220
103. Sosnovik D.E., and Weissleder R. Emerging concepts in molecular MRI. Curr. Opin. Biotechnol. 18 (2007) 4-10
104. Stark J.A., Davies K.E., Williams S.R., and Luckman S.M. Functional magnetic resonance imaging and c-Fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine. NeuroImage 31 (2006) 1228-1237
105. Stehling M.K., Turner R., and Mansfield P. Echo-planar imaging: magnetic resonance imaging in a fraction of a second. Science 254 (1991) 43-50
106. Steward C.A., Marsden C.A., Prior M.J., Morris P.G., and Shah Y.B. Methodological considerations in rat brain BOLD contrast pharmacological MRI. Psychopharmacology (Berl.) 180 (2005) 687-704
107. 11C](+)McN5652. Synapse 20 (1995) 37-43
108. Toda N., and Fujita Y. Responsiveness of isolated cerebral and peripheral arteries to serotonin, norepinephrine, and transmural electrical stimulation. Circ. Res. 33 (1973) 98-104
109. Tuor U.I., McKenzie E., and Tomanek B. Functional magnetic resonance imaging of tonic pain and vasopressor effects in rats. Magn. Reson. Imaging 20 (2002) 707-712
110. Van Camp N., D'Hooge R., Verhoye M., Peeters R.R., De Deyn P.P., and Van der Linden A. Simultaneous electroencephalographic recording and functional magnetic resonance imaging during pentylenetetrazol-induced seizures in rat. NeuroImage 19 (2003) 627-636
111. Vaughan C.W., and Christie M.J. Presynaptic inhibitory action of opioids on synaptic transmission in the rat periaqueductal grey in vitro. J. Physiol. 498 Pt 2 (1997) 463-472
112. Viswanathan A., and Freeman R.D. Neurometabolic coupling in cerebral cortex reflects synaptic more than spiking activity. Nat. Neurosci. 10 (2007) 1308-1312
113. Wechsler L.R., Savaki H.E., and Sokoloff L. Effects of d- and l-amphetamine on local cerebral glucose utilization in the conscious rat. J. Neurochem. 32 (1979) 15-22
114. Xi Z.X., Wu G., Stein E.A., and Li S.J. GABAergic mechanisms of heroin-induced brain activation assessed with functional MRI. Magn. Reson. Med. 48 (2002) 838-843
115. Yang Y., Gu H., and Stein E.A. Simultaneous MRI acquisition of blood volume, blood flow, and blood oxygenation information during brain activation. Magn. Reson. Med. 52 (2004) 1407-1417
116. von Zur Muhlen C., Sibson N.R., Peter K., Campbell S.J., Wilainam P., Grau G.E., Bode C., Choudhury R.P., and Anthony D.C. A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. J. Clin. Invest. 118 (2008) 1198-1207